View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare Ho...

Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22nd, 2024, with a live fireside chat scheduled for 9:00-9:40 am ET. The Company will also be hosting one-on-one meetings with investors in conjunction with the Conference. To register for the presentatio...

 PRESS RELEASE

Kohl’s Declares Quarterly Dividend

MENOMONEE FALLS, Wis.--(BUSINESS WIRE)-- The Board of Directors of Kohl’s Corporation (NYSE:KSS) today declared a regular quarterly dividend of $0.50 per share on the Company’s common stock. The dividend is payable June 26, 2024, to shareholders of record at the close of business on June 12, 2024. About Kohl’s Kohl’s (NYSE: KSS) is a leading omnichannel retailer built on a foundation that combines great brands, incredible value and convenience for our customers. Kohl's serves millions of families in our more than 1,100 stores in 49 states, online at , and through our Kohl's App. For a list...

 PRESS RELEASE

Kohl’s Corporation Holds Annual Shareholders Meeting

MENOMONEE FALLS, Wis.--(BUSINESS WIRE)-- Kohl’s Corporation (NYSE:KSS) (“Kohl’s” or the “Company”) today held its annual shareholders meeting. Following are the preliminary results for the five proposals voted upon by shareholders: Kohl’s shareholders elected Wendy Arlin, Michael J. Bender, Yael Cosset, Christine Day, H. Charles Floyd, Thomas A. Kingsbury, Robbin Mitchell, Jonas Prising, John E. Schlifske, Adrianne Shapira, and Adolfo Villagomez to the board of directors for one-year terms, with an average vote in favor of more than 96 percent of the votes cast; The advisory vote to appr...

 PRESS RELEASE

Vincerx Pharma Reports First Quarter 2024 Financial Results and Provid...

Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The National Institutes of Health (NIH) and Vincerx announced positive results from enitociclib Phase 1 combination study, reporting a fourth partial response (PR) in a patient with peripheral T-cell lymphoma (PTCL) Vincerx reported the first PR in a patient with transformed follicular lymphoma...

 PRESS RELEASE

Stryve Foods, Inc. Reports Fiscal 2024 First Quarter Results

Stryve Foods, Inc. Reports Fiscal 2024 First Quarter Results Retail Sales Velocity Increasing +23.2% Year-over-Year1Improved Adj. EBITDA Loss by 35.2% Year-over-Year3Reiterating Net Sales Guidance Range of $24M to $30M PLANO, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), an emerging healthy snacking platform and leader in the air-dried meat snack industry in the United States, today reports financial and operating results for the three months ended March 31, 2024. Q1 2024 – Improved Mix and Growing MomentumThe Company has continue...

 PRESS RELEASE

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phas...

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology Association (EHA) Annual Meeting KT-333 Phase 1 study ongoing with additional data expected in the second half of 2024 WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) --   (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medi...

 PRESS RELEASE

CRN Recognizes 7 Employees at Climb Channel Solutions on the 2024 Wome...

CRN Recognizes 7 Employees at Climb Channel Solutions on the 2024 Women of the Channel List and Names Climb’s VP of Marketing Worldwide as one of the 2024 Women of the Channel Power 100 EATONTOWN, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB), announced Monday, May 13, 2024 that ®, a brand of , has named seven women at Climb Channel Solutions to the Women of the Channel list for 2024 and the Climb VP of Marketing Worldwide to the 2024 Women of the ...

Jay Kornreich ... (+3)
  • Jay Kornreich
  • Richard Anderson
  • Sydnie Rohme
 PRESS RELEASE

Stryve Foods, Inc. Announces Timing of Fiscal 2024 First Quarter Resul...

Stryve Foods, Inc. Announces Timing of Fiscal 2024 First Quarter Results PLANO, Texas, May 12, 2024 (GLOBE NEWSWIRE) -- Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), an emerging healthy snack and eating platform disrupting traditional consumer packaged goods (CPG) categories, and a leader in the air-dried meat snack industry in the United States, today announces that it will release its fiscal 2024 first quarter results on Tuesday, May 14, 2024, after the market closes. In conjunction with the release, the Company has scheduled a conference call that will be hosted at 4:3...

 PRESS RELEASE

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Update...

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam $126.3 Million In Total Gross Proceeds from Warrant Distribution.Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam.Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million compared to a net loss o...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch